Nastech and Merck & Co. entered into license agreement to develop and commercialize Nastech’s Peptide YY 3-36 (PYY) that is in phase I clinical trials for treating obesity. The deal could be worth up to US$346 M to Nastech if specific milestones and sales targets are met.